Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

Summary

Karyopharm negotiated an extension on debt payments to pursue creditor discussions or business opportunities. Amgen is exploring expanded use of Imdelltra while BridgeBio's oncology spinout raised $275 million for development plans.